Bolt Biotherapeutics, Inc. Fair Value, Assets, Level 1 to Level 2 Transfers, Amount
Bolt Biotherapeutics, Inc. (BOLT) had Fair Value, Assets, Level 1 to Level 2 Transfers, Amount of $0 as of 2022-06-30, per its 10-Q filed 2022-08-10.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount · last filed 2022-08-10
- 2022-06-30: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2021-12-31: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2021-09-30: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2021-06-30: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
| Period end | Fair Value, Assets, Level 1 to Level 2 Transfers, Amount |
|---|---|
| 2022-06-30 | $0.00 10-Q · filed 2022-08-10 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-30 |
| 2021-09-30 | $0.00 10-Q · filed 2022-05-12 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-30 |
| 2020-09-30 | $0.00 10-Q · filed 2022-05-12 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |